Contact Kinex Pharmaceuticals

About Us Team Pipeline News Contact Us Careers Home
Kinex Named to Science Coalition List

Kinex to Present at the 101st Annual AACR Meeting

Kinex Technology Highlighted at American Chemical Society Symposium

Charles E. Lannon Appointed as Vice-Chairman of the Board at Kinex Pharmaceuticals

Kinex Pharmaceuticals Initiates a Phase 2 Clinical Trial of KX2-391 in Patients with Prostate Cancer

More headlines ...

Kinex News


Back to headlines

October 30, 2008
Kinex completes another successful round of financing

Kinex Pharmaceuticals recently raised $3.4 million through a private placement among its existing shareholders. This round brings the total raised in equity capital and grants to approximately $15 million, since its inception in 2004.

Kinex is developing Next Generation Cancer Drugs and among them is KX2-391 that is currently in late Phase 1 human clinical trials. Several Phase 2 trials are in the planning stage and are scheduled to be launched in mid-2009. Kinex has used its proprietary technology platform to design and synthesize non-ATP competitive kinase inhibitors; a new class of drugs that promise to deliver effective therapy with minimal side effects. KX2-391 is being evaluated in patients with solid tumors in Phase 1 trials at MD Anderson Cancer Center, Roswell Park Cancer Institute and Fox Chase Cancer Institute.

The Company’s pipeline is focused on kinase targets for cancer and immunological-based diseases. A second cancer compound will enter full pre-clinical development later this year.